Biography

Florian Schödel graduated in medicine at the Technical University, Munich, and earned doctorates in Transplantation Immunology and Medical Microbiology (Dr. med. Dr. med. habil.) from the University of Munich (LMU). He holds an adjunct faculty appointments at the LMU and held one at the Biodesign Center of the ASU. Florian’s research at the Max-Planck Institute for Biochemistry, at Scripps, WRAIR and INSERM focused on hepatitis B structure and molecular biology and on novel recombinant vaccines against multiple infectious diseases.

Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories. He has led the clinical teams responsible for several successful vaccine filings. He joined MRL in 1996,  leading EU vaccine clinical trials and the clinical development of rotavirus, measles, mumps, varicella and rubella vaccines. As the clinical liaison to an EU joint venture (SP-MSD) he participated in the development of pediatric combination vaccines. He led clinical teams in vaccines and biologics and contributed to clinical and analytical research development.

In 2010, Florian founded Philimmune LLC, providing advice on pharmaceutical development with a focus on vaccines and biologicals. Current and past clients include GSK, Intercell, Ancora Pharmaceuticals, Variation Biologicals, Takeda International, Synthetic Genome Vaccine Institute, Gilead, Biogen, Amgen, Illiad Biotechnologis, Iaso Therapeutics, Menarini, Minervax, Sequoia, Merck & Co., Inc., VaxynEthic, Biological E, Moderna, Inc., Enumeral, X-Vax and Novadigm. Florian has also served as an advisor to PATH, the BMGF, the Sabin Institute, the WHO and the Biodesign Center at ASU.